Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Rule 8.3- Torex Retail Plc

13 Apr 2007 15:33

GLG Partners LP13 April 2007 FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the Takeover Code) 1. KEY INFORMATION Name of person dealing (Note 1) GLG PARTNERS LP Company dealt in Torex Retail Plc Class of relevant security to which CONVERTIBLE BOND the dealings being disclosed relate (Note 2) Date of dealing 12-Apr-2007 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevantsecurity dealt in (Note 3) Long Short Number (%) Number (%) (1) Relevant securities 5.5% 8,500,000 13.08%convertible subordinated bonds due 2011 (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total 8,500,000 13.08% (b) Interests and short positions in relevant securities of the company, otherthan the class dealt in (Note 3) Class of relevant security: Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options) (5,133,908) (1.24%) (3) Options and agreements to purchase/sell Total (5,133,908) (1.24%) (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5) Sale (500,000) 70.00 (b) Derivatives transactions (other than options) Product Long/short Number of Price per name, e.g. (Note 6) securities unit (Note 5)CFD (Note 7) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, Expiry Option name,e.g. selling, securities price e.g. date money call purchasing, to which American, paid/ option varying the option European received etc. relates etc. per unit (Note 7) (Note 5) (ii) Exercising Product name, Number of Exercise price per unit e.g. call option securities (Note 5) (d) Other dealings (including new securities) (Note 4) Nature of transaction Details Price per unit (Note 8) (if applicable) (Note 5) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. .............................................................................. Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure 13.04.07 Contact name ALISON O'NEILL Telephone number 020 7016 7423 If a connected EFM, name of offeree N/A/offeror with which connected If a connected EFM, state nature of N/Aconnection (Note 10) Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jan 20267:00 amRNSSecondary Trading Following Cancellation
7th Jan 20267:00 amRNSCancellation - Tissue Regenix Group Plc
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
17th Dec 20256:00 pmRNSTissue Regenix Group
8th Dec 20257:00 amRNSUpdate re. proposed cancellation of shares
4th Dec 20252:40 pmRNSProposed £17.5m CLN raise, cancellation of Trading
1st Dec 20257:00 amRNSFurther re. financial update and funding plans
7th Nov 20257:00 amRNSFinancial update and funding plans
22nd Oct 20253:29 pmRNSStatement re. Suspension
22nd Oct 20252:02 pmRNSSuspension - Tissue Regenix Group PLC
17th Oct 20257:00 amRNSCFO joins Board
16th Oct 20257:00 amRNSUpdate re. FY24 & H125 restatement & Board Changes
9th Oct 20257:00 amRNSHolding(s) in Company
6th Oct 20253:29 pmRNSHolding(s) in Company
3rd Oct 20253:01 pmRNSHolding(s) in Company
2nd Oct 20254:43 pmRNSHolding(s) in Company
1st Oct 20255:35 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
17th Sep 20257:00 amRNSNotice of Results
8th Sep 20257:01 amRNSHalf-Year Trading Update and Notice of Results
8th Sep 20257:00 amRNSBoard Changes
1st Aug 20257:00 amRNSDirectorate Change
23rd Jul 20251:52 pmRNSResult of AGM
4th Jul 20257:00 amRNSGrant of share options
27th Jun 20257:00 amRNSPosting of Annual Report & Notice of AGM
25th Jun 20257:00 amRNSFinal results for the year ended 31 December 2024
9th Jun 20257:00 amRNSCE & UKCA certification for OrthoPure® XT
24th Apr 20259:38 amRNSForm 8.5 (EPT/NON-RI)- Tissue Regenix Group Plc
15th Apr 20259:23 amRNSForm 8.5 (EPT/NON-RI)
10th Apr 20259:09 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 202510:45 amRNSForm 8.5 (EPT/NON-RI)
8th Apr 20257:00 amRNSConclusion of Strategic Review & Offer Period
7th Apr 20258:46 amRNSForm 8.5 (EPT/NON-RI)
1st Apr 20259:12 amRNSForm 8.5 (EPT/NON-RI)
31st Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
27th Mar 20257:00 amRNSEuropean patent granted
25th Mar 20258:58 amRNSForm 8.5- Tissue Regenix Group Plc
21st Mar 20258:36 amRNSForm 8.5 (EPT/NON-RI)
20th Mar 20259:19 amRNSForm 8.5 (EPT/NON-RI)
19th Mar 20258:55 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20257:00 amRNSCompany update
12th Mar 20259:27 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 20259:30 amRNSForm 8.5 (EPT/NON-RI)
6th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
5th Mar 20258:54 amRNSForm 8.5 (EPT/NON-RI)
4th Mar 20259:28 amRNSForm 8.5 (EPT/NON-RI)
3rd Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 20258:56 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.